Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke
- PMID: 23168217
- DOI: 10.1016/j.jstrokecerebrovasdis.2012.10.005
Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke
Abstract
Background: A German study diagnosed 4% of young cryptogenic ischemic stroke patients with Fabry disease, an X-linked lysosomal storage disease caused by mutations in the alpha-galactosidase A (α-GAL-A) gene resulting in an accumulation of glycosphingolipids. A lower prevalence was found in other geographic regions.
Aim: To determine the prevalence of Fabry disease in a Canadian population of young cryptogenic ischemic stroke patients.
Materials and methods: Patients with cryptogenic ischemic stroke at age 16-55 were retrospectively identified in our institutional stroke database and underwent a focused clinical evaluation. We sequenced the α-GAL-A gene and measured the levels of blood globotriaosylsphingosine in subjects with mutations of undetermined pathogenicity. Fabry disease was diagnosed in patients with pathogenic mutations or increased levels of blood globotriaosylsphingosine.
Results: Ninety-three of 100 study subjects had normal α-GAL-A gene polymorphisms. Seven had mutations of undetermined pathogenicity, including one with increased globotriaosylsphingosine (prevalence, 1%; 95% confidence interval, <.01%-6%). No subjects had angiokeratomas or other clinical manifestations of Fabry disease. Investigation results suggestive of Fabry disease (idiopathic hypertrophic cardiomyopathy, proteinuria, vertebrobasilar dolichoectasia, and the pulvinar sign) were found only in subjects with normal α-GAL-A genes. Apart from the 100 study subjects, our database included another patient with a family history of Fabry disease and a pathogenic mutation identified before her ischemic stroke presentation as the first clinical manifestation of Fabry disease. Both Fabry patients experienced recurrent ischemic stroke.
Conclusions: Fabry disease accounts for a small proportion of young Canadians with cryptogenic ischemic stroke. Identification of Fabry biomarkers remains a research priority to delineate stroke patients disserving routine screening.
Keywords: Fabry disease; Stroke; cryptogenic stroke; prevalence; stroke etiology; stroke genetics; stroke in the young.
Copyright © 2013 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.Lancet. 2005 Nov 19;366(9499):1794-6. doi: 10.1016/S0140-6736(05)67635-0. Lancet. 2005. PMID: 16298216
-
Fabry's disease: a prospective multicenter cohort study in young adults with cryptogenic stroke.Int J Stroke. 2012 Apr;7(3):265-73. doi: 10.1111/j.1747-4949.2011.00734.x. Epub 2012 Jan 20. Int J Stroke. 2012. PMID: 22264232
-
Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.Clin Neurol Neurosurg. 2013 Jul;115(7):1088-93. doi: 10.1016/j.clineuro.2012.11.003. Epub 2012 Dec 4. Clin Neurol Neurosurg. 2013. PMID: 23219219
-
Neurological complications of Anderson-Fabry disease.Curr Pharm Des. 2013;19(33):6014-30. doi: 10.2174/13816128113199990387. Curr Pharm Des. 2013. PMID: 23448452 Review.
-
Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature.Eur J Neurol. 2019 Mar;26(3):553-555. doi: 10.1111/ene.13775. Epub 2018 Sep 9. Eur J Neurol. 2019. PMID: 30103270 Free PMC article. Review.
Cited by
-
Prevalence of CADASIL and Fabry Disease in a Cohort of MRI Defined Younger Onset Lacunar Stroke.PLoS One. 2015 Aug 25;10(8):e0136352. doi: 10.1371/journal.pone.0136352. eCollection 2015. PLoS One. 2015. PMID: 26305465 Free PMC article.
-
Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review.Cureus. 2021 Nov 8;13(11):e19358. doi: 10.7759/cureus.19358. eCollection 2021 Nov. Cureus. 2021. PMID: 34925972 Free PMC article. Review.
-
Assessment of Peripheral Nervous System Alterations in Patients with the Fabry Related GLA-Variant p.A143T.Diagnostics (Basel). 2020 Nov 30;10(12):1027. doi: 10.3390/diagnostics10121027. Diagnostics (Basel). 2020. PMID: 33266233 Free PMC article.
-
Expanding the Neurological Phenotype of Anderson-Fabry Disease: Proof of Concept for an Extrapyramidal Neurodegenerative Pattern and Comparison with Monogenic Vascular Parkinsonism.Cells. 2024 Jun 29;13(13):1131. doi: 10.3390/cells13131131. Cells. 2024. PMID: 38994983 Free PMC article. Review.
-
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z. Orphanet J Rare Dis. 2016. PMID: 27142856 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical